consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013

Jorge Sánchez Lander y col.
287
carcinoma: A randomized phase III study of pegylated
liposomal doxorubicin versus topotecan. J Clin Oncol.
2001;19(14):3312-3322.
21. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda
E, Savarese A, et al. Phase III trial of gemcitabine
compared with pegylated liposomal doxorubicin in
progressive or recurrent ovarian cancer. J Clin Oncol.
2008;26(6):890-896.
22. Teneriello MG, Tseng PC, Crozier M, Encarnacion C,
Hancock K, Messing MJ, et al. Phase II evaluation of
nanoparticle albumin-bound paclitaxel in platinumsensitive
patients with recurrent ovarian, peritoneal, or
fallopian tube cancer. J Clin Oncol. 2009;27(9):1426-
1431.
23. Coleman RL, Brady WE, McMeekin DS, Rose PG,
Soper JT, Lentz SS, et al. A phase II evaluation of
nanoparticle, albumin-bound (nab) paclitaxel in the
treatment of recurrent or persistent platinum-resistant
ovarian, fallopian tube, or primary peritoneal cancer: A
Gynecologic Oncology Group study. Gynecol Oncol.
2011;122(1):111-115.
24. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano
G, Noberasco C, et al. Trabectedin for women with
ovarian carcinoma after treatment with platinum and
taxanes fails. J Clin Oncol. 2005;23(9):1867-1874.
25. Krasner CN, McMeekin DS, Chan S, Braly PS,
Renshaw FG, Kaye S, et al. A Phase II study of
trabectedin single agent in patients with recurrent
ovarian cancer previously treated with platinum-based
regimens. Br J Cancer. 2007;97(12):1618-1624.
26. Hurteau JA, Brady MF, Darcy KM, McGuire WP,
Edmonds P, Pearl ML, et al. Randomized phase
III trial of tamoxifen versus thalidomide in women
with biochemical-recurrent-only epithelial ovarian,
fallopian tube or primary peritoneal carcinoma
after a complete response to first-line platinum/
taxane chemotherapy with an evaluation of serum
vascular endothelial growth factor (VEGF): A
Gynecologic Oncology Group Study. Gynecol Oncol.
2010;119(3):444-4450.
27. Smyth JF, Gourley C, Walker G, MacKean MJ,
Stevenson A, Williams AR, et al. Antiestrogen therapy
is active in selected ovarian cancer cases: The use of
letrozole in estrogen receptor-positive patients. Clin
Cancer Res. 2007;13(12):3617-3622.
28. Seewaldt VL, Greer BE, Cain JM, Figge DC, Tamimi
HK, Brown WS, et al. Paclitaxel (Taxol) treatment
for refractory ovarian cancer: Phase II clinical trial.
Am J Obstet Gynecol. 1994;170(6):1666-1670.
29. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl
H, et al. Paclitaxel (Taxol) in relapsed and refractory
ovarian cancer: the UK and Eire experience. Br J
Cancer. 1995;72(4):1016-1019.
30. Bruzzone M, Catsafados E, Miglietta L, Amoroso D,
Pedulla F, Giannessi PG, et al. Salvage chemotherapy
with paclitaxel in platinum-resistant advanced ovarian
cancer patients. Oncology. 1996;53(5):349-353.
31. Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley
G, Rondinón M, Blajman C, et al. Paclitaxel in
platinum-resistant ovarian cancer patients. Argentine
Multicenter Taxol Group. Semin Oncol. 1997;24(5
Suppl 15):S15-53.
32. Peng LH, Chen XY, Wu TX. Topotecan for
ovarian cancer. Cochrane Database Syst Rev.
2008;(2):CD005589.
33. Gordon AN, Fleagle JT, Guthrie D, Parkin DE,
Gore ME, Lacave AJ. Recurrent epithelial ovarian
carcinoma: A randomized phase III study of pegylated
liposomal doxorubicin versus topotecan. J Clin Oncol.
2001;19(14):3312-3322.
34. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study
30-49 Investigators. Long-term survival advantage for
women treated with pegylated liposomal doxorubicin
compared with topotecan in a phase 3 randomized
study of recurrent and refractory epithelial ovarian
cancer. Gynecol Oncol. 2004;95(1):1-8.
35. Gynecologic Oncology Group, Markman M, Blessing
J, Rubin SC, Connor J, Hanjani P, et al. Phase II trial
of weekly paclitaxel (80 mg/m 2 ) in platinum and
paclitaxel-resistant ovarian and primary peritoneal
cancers: A Gynecologic Oncology Group study.
Gynecol Oncol. 2006;101(3):436-440.
36. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes
Ed, Steger M, Nelson-Taylor T, et al. Docetaxel for
patients with paclitaxel-resistant Müllerian carcinoma.
J Clin Oncol. 2000;18(14):2733-2739.
37. Coleman RL, Brady WE, McMeekin DS, Rose PG,
Soper JT, Lentz SS, et al. A phase II evaluation of
nanoparticle, albumin-bound (nab) paclitaxel in the
treatment of recurrent or persistent platinum-resistant
ovarian, fallopian tube, or primary peritoneal cancer: A
Gynecologic Oncology Group study. Gynecol Oncol.
2011;122(1):111-115.
38. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau
A, Bogenrieder T, et al. Topotecan weekly vs.,
conventional 5-day schedule in patients with platinumresistant
ovarian cancer: A randomized multicenter
phase II trial of the North-Eastern German Society
of Gynecological Oncology Ovarian Cancer Study
Group. J Clin Oncol. 2011;29(2):242-248.
Rev Venez Oncol